From the Journals

Intra-articular steroid/lidocaine injection improves hip arthritis pain, function


(Reuters) – A single injection into the hip of steroid and local anesthetic improved pain and function in patients with hip osteoarthritis in a randomized controlled trial, with most of the benefit seen early after treatment.

Researchers at two community-based clinics in England assigned 199 volunteers to receive either an ultrasound guided intra-articular hip injection of 40 mg triamcinolone acetonide and 4 mL 1% lidocaine hydrochloride combined with best current treatment, an injection of lidocaine alone plus best current treatment, or best current treatment alone.

Patients were at least 40 years old, with moderate to severe hip pain on most days for at least 6 weeks and a diagnosis of hip osteoarthritis within the last 2 years based on clinical history, examination, and imaging. Patients were excluded if they had steroid injections in the past 3 months, previous hip surgery, or infection.

The primary outcome was pain at 6 months as reflected on a 0-10 numerical rating score. Secondary outcomes included pain, stiffness and physical function (WOMAC scores), pain self-efficacy, patient’s impression of pain, general health, return to work, and satisfaction with treatment. Follow-up questionnaires were mailed to patients at 2 weeks and at 2, 4, and 6 months; the average weighted follow-up rate was 93%.

Over 6 months, mean improvement in hip pain intensity was greater in patients who received triamcinolone with lidocaine than in those who got best current treatment alone: mean difference –1.43 (95% confidence interval –2.15 to –0.72), P < .001; standardized mean difference –0.55 (–0.82 to –0.27).

Most improvements were noted early, with a greater mean improvement reported at 2 weeks (–3.17 [–4.06 to –2.28], P < .001; –1.21, [–1.55 to –0.81]) and 2 months (–1.81 [–2.71 to –0.92], P < .001; –0.69 [–1.03 to –0.35]), but not at 4 months or 6 months, according to a report by Dr. Zoe Paskins of Keele (England) University and colleagues in The BMJ.

There was no difference in hip pain intensity over 6 months between the triamcinolone-lidocaine and the lidocaine injection groups (–0.52 [–1.21 to 0.18]). However, significantly higher overall mean improvement was seen in secondary outcomes such as pain self-efficacy, quality of life, WOMAC score, global impression of change, and sleep disturbances. Again, differences were greatest at earlier time points rather than during later follow up.

The presence of ultrasound confirmed synovitis or effusion was associated with a significant interaction effect favoring treatment with triamcinolone-lidocaine (–1.70 [–3.10 to –0.30]).

One participant in the triamcinolone-lidocaine group with a bioprosthetic aortic valve died from subacute bacterial endocarditis 4 months after the intervention, deemed possibly related to the trial treatment. The authors advise “caution ... in patients with risk factors for, or signs of, infection.”

In community settings, they concluded, “an ultrasound guided intra-articular hip injection of corticosteroid and local anesthetic, administered with advice and education, is a clinically effective treatment for rapid and sustained symptom response compared with advice and education alone for people with hip osteoarthritis.”

Reuters Health Information © 2022

Next Article: